08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cholesteryl ester transfer protein (CETP)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and rodent studies identified a triphenylethanamine-based inhibitor of CETP that could help treat atherosclerosis. Chemical synthesis and in vitro testing of triphenylethanamine analogs identified a lead compound ( BMS-795311...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Simcere, Bristol-Myers deal

Bristol-Myers and Simcere expanded a 2010 deal to include the development and commercialization of subcutaneous Orencia abatacept in China to treat rheumatoid arthritis (RA). Simcere will be responsible for conducting and funding development and regulatory...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Simcere, Bristol-Myers deal

Bristol-Myers granted Simcere exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere to the small molecule cholesteryl ester transfer protein (CETP) inhibitor. Financial terms were not disclosed. Last...
08:00 , Dec 19, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.15 (24%) to $0.78 on Tuesday after FDA's Psychopharmacologic Drugs Advisory Committee voted 9-8, with one abstention, in favor of recommending approval of inhaled Adasuve loxapine to treat...
02:01 , Dec 15, 2011 |  BC Extra  |  Company News

BMS, Simcere in deal for CETP inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) granted Simcere Pharmaceutical Group (NYSE:SCR) exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere. BMS-795311 is a small molecule cholesteryl ester transfer protein (CETP)...